GoIndustry DoveBid appoints SVP of North American sales
Romie Castelli returns to the company he originally joined in 2002
Castelli takes responsibility for directing GoIndustry DoveBid’s sales and marketing efforts in North America. He was most recently senior vice president of corporate services at Great American Group. Before that, as senior vice president of North America at DoveBid, prior to its acquisition by GoIndustry in 2008, he was responsible for the DoveBid sales force.
Castelli joined DoveBid in 2002 through acquisition, having been vice president of sales for ZoneTrader.
You may also like
Packaging
Sharp Services invests $100m to expand global sterile and packaging capacity across US and Europe
The investment will boost sterile fill/finish, injectable packaging and oral solid dose capacity across Sharp's US and European sites, strengthening its clinical and commercial manufacturing network to meet growing pharmaceutical demand
Finance
MilliporeSigma to acquire JSR Life Sciences’ chromatography business, boosting Protein A purification capabilities
The acquisition expands MilliporeSigma’s downstream bioprocessing portfolio with JSR’s Amsphere Protein A resin technology, enhancing efficiency and reliability in monoclonal antibody and therapeutic protein production
Finance
Wilmington PharmaTech secures further funding for its expansion from Curewell Capital
The CDMO's partnership with Curewell will provide significant growth capital to expand WPT’s manufacturing capacity and further scale its end-to-end capabilities in producing a full range of small molecule API in the US
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Finance
Kailera Therapeutics secures $600m in Series B financing to advance next-generation obesity therapies
The funding will support the advancement of Kailera’s obesity portfolio, including a global Phase III clinical programme of Kailera’s lead candidate KAI-9531, an injectable dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss